Life Sciences

  • April 29, 2026

    Feds Say Lack Of Injury Dooms Gold Card Program Challenge

    The Trump administration said a suit challenging the gold card visa program's legality must be thrown out because the immigrants and academic professionals union that filed it can't show the program hurts their chances at getting visas.

  • April 29, 2026

    High Court Seeks Path To Limited Ruling On 'Skinny Labels'

    The U.S. Supreme Court on Wednesday appeared reluctant to craft new standards for deciding whether makers of generic drugs that use so-called skinny labels have encouraged others to infringe patents, with several justices saying existing law is sufficient to make a decision.

  • April 29, 2026

    Deloitte Can't Duck Bulk Of Vax Software Theft Suit

    Deloitte must face an inventor's trade secrets misappropriation claims accusing the consulting giant of ripping off her firm's proprietary vaccination management system and securing a multimillion-dollar government contract to track the rollout of COVID-19 vaccines.

  • April 29, 2026

    Squires Snubs 10 IPRs While 4 Pass Muster In Latest Order

    U.S. Patent and Trademark Office Director John Squires rejected 10 petitions for America Invents Act patent reviews and granted four challenges in an order marking the roughly half-year mark since he took over the duty of making institution decisions.

  • April 29, 2026

    CEO Stole From His Company To Buy Mansion, SEC Says

    The former CEO of a California-based pharmaceutical company agreed Wednesday to pay the U.S. Securities and Exchange Commission $30,000 to end a lawsuit accusing him of misappropriating $3.2 million in company funds partly to buy a Beverly Hills mansion.

  • April 29, 2026

    3 Federal Circuit Clashes To Watch In May

    The Federal Circuit's May argument slate includes appeals of invalidity decisions and sanctions tied to VLSI Technology's multibillion-dollar chip patent dispute with Intel, as well as Amazon's challenge to a cloud storage patent verdict against it for over half a billion dollars.

  • April 29, 2026

    Novo Nordisk Rejects Claim It Influences GLP-1 Market

    Pharmaceutical giant Novo Nordisk told a Texas federal judge that it does not control the GLP-1 market and has not attempted to crush its competition in a bid to dismiss an antitrust suit it is facing.

  • April 29, 2026

    PBMs Say Michigan AG Price-Fixing Suit Is Unsound

    Pharmacy benefit managers Express Scripts, Evernorth Health and Prime Therapeutics have bolstered their effort to escape a federal price-fixing suit brought against them by Michigan's attorney general by arguing the statutes cited in the complaint do not apply to them.

  • April 29, 2026

    Teva Acquires Tourette's Drugmaker For Up To $900M

    Biopharmaceutical company Teva Pharmaceuticals, advised by Faegre Drinker Biddle & Reath LLP, on Wednesday announced plans to acquire Bradley Arant Boult Cummings LLP-advised Emalex Biosciences for up to $900 million.

  • April 29, 2026

    Bausch Balks At Suspected Tweak In Price-Fixing Deals

    A stipulation between state attorneys general and private plaintiffs suing generic-drug makers for alleged price-fixing seems to reflect a change in the states' earlier deal to release claims against Bausch entities, the companies said in asking a Connecticut federal judge to maintain the status quo.

  • April 29, 2026

    AbbVie Seeks Early Win Over HHS In Botox Drug Price Suit

    When the federal government included Botox in Medicare's drug price negotiation program, which allows Medicare officials to negotiate for lower drug prices, it overstepped its authority, drugmaker AbbVie Inc. told a D.C. federal court, arguing the cosmetic drug and migraine treatment is a "plasma-derived" product ineligible for price controls.

  • April 29, 2026

    Ropes & Gray Guides Italy's Chiesi On $1.9B US Biotech Deal

    Chiesi Group said Wednesday it will acquire KalVista Pharmaceuticals in a deal valued at about $1.9 billion, expanding the Italian biopharmaceutical company's rare disease portfolio with a newly approved treatment for a rare hereditary swelling disorder. 

  • April 29, 2026

    Hogan Lovells Rehires Baker McKenzie Chair As Partner In DC

    Hogan Lovells has rehired an attorney who was most recently the chair of Baker McKenzie's U.S. healthcare and life sciences regulatory practice, who advises life sciences, food, consumer platform and technology companies.

  • April 28, 2026

    Allergan Seeks Sanctions Over Discovery In Botox Fight

    Botox manufacturer Allergan has asked a Tennessee federal judge to sanction Revance Therapeutics, claiming its attorneys made misrepresentations to run out the clock on discovery and prevent Allergan from obtaining essential information in a case alleging theft of trade secrets.

  • April 28, 2026

    5th Circ. Judge 'Hung Up' On FDA Vape Denial Reasoning

    A Fifth Circuit judge on Tuesday pressed the U.S. Food and Drug Administration on how it reviews applications from flavored vape manufacturers, asking why repeatedly denying applicants on similar grounds should not be treated as a rule requiring notice-and-comment.

  • April 28, 2026

    Teleflex Settles Catheter Patent Case Against Medtronic

    Medical device company Teleflex and Medtronic have reached a settlement to end a catheter patent dispute from which a judge recused himself after explaining he was "at a loss" on how to proceed.

  • April 28, 2026

    Ex-Fauci Adviser Charged With Concealing COVID Records

    Federal prosecutors have charged a former adviser to Dr. Anthony Fauci with deleting government emails and using his personal email account to dodge public records requests about the origins of the COVID-19 virus.

  • April 28, 2026

    Purdue Pharma's $5.5B Plea Deal Clinched As Survivors Protest

    OxyContin maker Purdue Pharma LP has to pay a $3.5 billion fine and forfeit an additional $2 billion, more than five years after it pled guilty to criminal charges related to its role in the opioid crisis, a New Jersey federal judge said Tuesday.

  • April 28, 2026

    MedMal Case Volume Declines, But Doctor Risks Remain High

    While the volume of malpractice lawsuits against U.S. physicians has dropped in recent years, that doesn't mean the threat of legal liability is dissipating, according to a report released Monday by the American Medical Association. 

  • April 28, 2026

    Paul Hastings, Gibson Dunn Steer $739M Ligand-Xoma Deal

    Ligand Pharmaceuticals said it plans to purchase XOMA Royalty in a $739 million deal combining the two biotechnology royalty aggregator companies advised by Gibson Dunn & Crutcher LLP and Paul Hastings LLP.

  • April 28, 2026

    Walgreens Can't Use Recording To Undo Investor Claim In Ill.

    An Illinois federal judge has said she won't toss a claim brought by shareholders alleging a former Walgreens president made a false and misleading statement during an investor conference, rejecting the company's argument that an audio recording of that conference warranted a second look at her dismissal ruling.

  • April 28, 2026

    Chinese Man Extradited From Italy Over COVID Data Theft

    A Chinese citizen has appeared before a Houston federal court after being extradited from Italy to face charges for his alleged role in the Microsoft "HAFNIUM" cyberattack that was allegedly orchestrated by the Chinese government to target U.S. COVID-19 research.

  • April 28, 2026

    Hikma, Cipla Cut Deals In Pfizer Heart Drug Patent Case

    Hikma Pharmaceuticals PLC and Cipla Ltd. have reached settlements with Pfizer Inc. in a case over the two defendants' efforts to create generic versions of the heart medication Vyndamax.

  • April 28, 2026

    Maryland Justices Allow IVF Cost Class Action To Proceed

    A Maryland couple can pursue a proposed class action against a health insurer that they say wrongfully denied coverage for embryo thawing in connection with an in vitro fertilization procedure, the Maryland Supreme Court has ruled, finding that the insurer's subsequent payment of the claim doesn't moot the suit.

  • April 28, 2026

    Eli Lilly Inks $2.25B AI Genetics Research Pact With Profluent

    AI-focused biotech Profluent said Tuesday it has entered a multiprogram, strategic research collaboration with Eli Lilly and Co. to treat diseases with high unmet need, in a deal that involves an upfront payment and up to $2.25 billion in additional milestone payments. 

Expert Analysis

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

  • Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts

    Author Photo

    Recent memoranda from the U.S. Patent and Trademark Office, along with some of the first patents issued under Director John Squires, indicate a recalibration of the subject matter eligibility landscape, signaling a renewed emphasis on concrete technological improvements and a potentially pro-AI stance, say attorneys at Banner Witcoff.

  • Tax Court Ruling Signals Cross-Border Loan Scrutiny

    Author Photo

    The U.S. Tax Court’s recent decision in Aventis v. Commissioner compounds ongoing regulatory focus on debt originations and should prompt practitioners to assess their existing cross-border lending structures for potential exposure to U.S. federal income tax, say attorneys at Eversheds.

  • Lessons From Justices' Split On Major Questions Doctrine

    Author Photo

    The justices' varied opinions in Learning Resources v. Trump, which held the International Emergency Economy Powers Act did not confer the power to impose tariffs, offer a meaningful window into the U.S. Supreme Court's perspective on the major questions doctrine that will likely shape lower courts' approach to executive action challenges, say attorneys at Venable.

  • Drug Wholesaler's DPA Shows Imperfect Efforts Still Count

    Author Photo

    Atlantic Biologicals’ recent deferred prosecution agreement with federal prosecutors for allegedly distributing controlled substances to pill mill pharmacies demonstrates that even subpar cooperation, when combined with genuine remediation and strategic advocacy, can yield outcomes that protect a company's long-term interests, says Jonathan Porter at Husch Blackwell.

  • Key Takeaways As HRSA Aims To Revive 340B Rebate Pilot

    Author Photo

    The U.S. Department of Health and Human Services' recent request for feedback on the 340B Rebate Model Pilot Program demonstrates that it intends to correct the model's procedural defects, which is positive news for participating manufacturers, but a setback for covered entities, say attorneys at Manatt.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.